Washington, DC, United States
Washington, DC, United States

Time filter

Source Type

News Article | May 23, 2017
Site: globenewswire.com

INNATE PHARMA TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON JUNE 23, 2017 Innate Pharma (the "Company" - Euronext Paris: FR0010331421 - IPH) will hold its Annual General Meeting of Shareholders ("AGM") on June 23, 2017, at 10:00 am in its headquarters, 117 avenue de Luminy, F-13009 Marseille. The Notice of Meeting of this Shareholders' Meeting was published on May 19, 2017, in the French official legal bulletin ("BALO"). It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this Meeting. It is also available . All documentation regarding this AGM will be made available to shareholders in accordance with existing regulations and will be available on the Company's website as of today . Among the resolutions, the following will be proposed during the AGM: Professor Jean-Charles Soria will replace Professor Michael Caligiuri, who has been named American Association for Cancer Research (AACR) President and resigned from the Supervisory board. Hervé Brailly, Chairman of the Supervisory board, commented: "On behalf of all Supervisory board members, I would like to express our deepest gratitude to Professor Caligiuri, who has just been named President of AACR, one of the most prestigious worldwide cancer associations, for his commitment to the Board during the four years of his mandate. His medical expertise and experience have been valuable assets to the Board. We propose the appointment of Professor Jean-Charles Soria to succeed him. Professor Jean-Charles Soria is an oncologist, Head of Drug Development department at Gustave Roussy cancer center, and a renowned world leader in the field of immuno-oncology. We are also pleased to propose the appointment of Bpifrance Participations, represented by Maïlys Ferrère. Bpifrance Participations holds Innate Pharma's shares since 2009 and has supported the Company ever since. This appointment of Bpifrance Participations as member of the Supervisory board shows once again their commitment to Innate Pharma. These proposals guarantee the wealth, diversity and complementarity of profiles which composed the Board and we will pursue our work thanks to the expertise of each of its members." Maïlys Ferrère is Director of the Large Venture Investment Pole within the Innovation Division of Bpifrance. Large Venture's mission is to provide long term capital to innovative French companies in areas with very strong growth with the goal of creating world leaders. The portfolio currently includes thirty companies in life sciences, digital and environmental technologies. Prior to this position, Maïlys Ferrère was an Investment Director at the Strategic Investment Fund between 2009 and 2012. She previously had a career in banking, specialized in equity capital markets in various financial institutions. Maïlys Ferrère is a member of the Boards of Directors or Supervisory boards of the following companies: DBV, Valneva SE, Pixium, Gensight and Euronext Paris. Professor Jean-Charles Soria is a medical oncologist and a Professor of Medicine and Medical Oncology at South-Paris University. He is a full-time cancer specialist at Institut Gustave Roussy. Professor Soria trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997. He gained a postgraduate degree and a PhD degree in molecular biology (fundamental basis of oncogenesis) in 2001, and completed his training with a two-year post-doctoral fellowship at MD Anderson Cancer Center, Houston, USA, where he has held an Adjunct Professorship since 2012. Professor Soria is also a member of the thoracic pathology committee at Gustave Roussy Cancer Center. He is a recognized expert on targeted therapies, immunotherapy and lung cancer. His main research interests are: early clinical development, pharmacodynamic biomarkers, lung cancer, immunotherapy and personalized medicine. He is also involved in translational research aspects related to precision medicine and tumor progression notably in lung cancer models (INSERM unit 981). Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight Paris time, will be able to attend. Shareholders holding "au porteur" (bearer) shares will need to obtain an "attestation de participation" (certificate of shareholding) from their brokers. This "attestation de participation" must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The "attestation de participation" may replace the admission card for shareholders wishing to attend the AGM in person. Written questions from shareholders must be received from the day of the publication of the official convocation to the AGM up until four business days prior to the AGM (by registered letter, addressed to the registered office, or by e-mail to investors@innate-pharma.com). Shareholders may obtain the legal documentation in preparation of the AGM (as described in article R. 225-83 of the French "Code de Commerce") by sending a request: Innate Pharma S.A. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The Company's aim is to become a fully-integrated biopharmaceutical company in the area of immunotherapy and focused on serious unmet medical needs in cancer. Innate Pharma has pioneered the discovery and development of checkpoint inhibitors to activate the innate immune system. Innate Pharma's innovative approach has resulted in three first-in-class, clinical-stage antibodies targeting natural killer cell receptors that may address a broad range of solid and hematological cancer indications as well as additional preclinical product candidates and technologies. Targeting receptors involved in innate immunity also creates opportunities for the Company to develop therapies for inflammatory diseases. The Company's expertise and understanding of natural killer cell biology have enabled it to enter into major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb and Sanofi. Based in Marseille, France, Innate Pharma has more than 170 employees and is listed on Euronext Paris. Learn more about Innate Pharma at www.innate-pharma.com. This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.


WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that a poster presentation that includes updated results from the ongoing Phase 1 clinical study of DCC-2618, the company’s pan-KIT and PDGFRα inhibitor, will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2 - 6, 2017, in Chicago IL. Details of the presentation are as follows: Poster Title: Pharmacokinetic-driven phase 1 study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients with gastrointestinal stromal tumor (GIST) and other solid tumors. Author: Filip Janku, M.D., Ph.D., The University of Texas MD Anderson Cancer Center Session: Poster Discussion Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics Abstract #: 2515 Date and Time: Monday, June 5, 2017, 8:00 AM – 11:30AM (CST) Poster Discussion Session: Monday, June 5, 2017 11:30 AM-12:45 PM (CST) “We are very pleased to present these important results and to provide an update on the clinical development of DCC-2618, our pan-KIT and PDGFRα inhibitor in development for difficult to treat, KIT and/or PDGFRα-driven cancers with limited therapeutic options,” said Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer. “These maturing data confirm earlier results presented at the 2016 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics,” added Oliver Rosen, M.D., Deciphera’s Chief Medical Officer. “The encouraging clinical activity achieved in patients with a broad spectrum of mutations and prior therapies in our Phase 1 study supports the impressive translational data presented last month at the 2017 American Association for Cancer Research (AACR) Annual Meeting”. About DCC-2618 DCC-2618 is currently in a first-in-human Phase 1 clinical trial. DCC-2618 is a pan-KIT and PDGFRα kinase switch control inhibitor in clinical development for the treatment of KIT and/or PDGFRα-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. About Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off’ or inactivated conformation. These therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their response to treatment.


News Article | May 23, 2017
Site: globenewswire.com

INNATE PHARMA TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON JUNE 23, 2017 Innate Pharma (the "Company" - Euronext Paris: FR0010331421 - IPH) will hold its Annual General Meeting of Shareholders ("AGM") on June 23, 2017, at 10:00 am in its headquarters, 117 avenue de Luminy, F-13009 Marseille. The Notice of Meeting of this Shareholders' Meeting was published on May 19, 2017, in the French official legal bulletin ("BALO"). It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this Meeting. It is also available . All documentation regarding this AGM will be made available to shareholders in accordance with existing regulations and will be available on the Company's website as of today . Among the resolutions, the following will be proposed during the AGM: Professor Jean-Charles Soria will replace Professor Michael Caligiuri, who has been named American Association for Cancer Research (AACR) President and resigned from the Supervisory board. Hervé Brailly, Chairman of the Supervisory board, commented: "On behalf of all Supervisory board members, I would like to express our deepest gratitude to Professor Caligiuri, who has just been named President of AACR, one of the most prestigious worldwide cancer associations, for his commitment to the Board during the four years of his mandate. His medical expertise and experience have been valuable assets to the Board. We propose the appointment of Professor Jean-Charles Soria to succeed him. Professor Jean-Charles Soria is an oncologist, Head of Drug Development department at Gustave Roussy cancer center, and a renowned world leader in the field of immuno-oncology. We are also pleased to propose the appointment of Bpifrance Participations, represented by Maïlys Ferrère. Bpifrance Participations holds Innate Pharma's shares since 2009 and has supported the Company ever since. This appointment of Bpifrance Participations as member of the Supervisory board shows once again their commitment to Innate Pharma. These proposals guarantee the wealth, diversity and complementarity of profiles which composed the Board and we will pursue our work thanks to the expertise of each of its members." Maïlys Ferrère is Director of the Large Venture Investment Pole within the Innovation Division of Bpifrance. Large Venture's mission is to provide long term capital to innovative French companies in areas with very strong growth with the goal of creating world leaders. The portfolio currently includes thirty companies in life sciences, digital and environmental technologies. Prior to this position, Maïlys Ferrère was an Investment Director at the Strategic Investment Fund between 2009 and 2012. She previously had a career in banking, specialized in equity capital markets in various financial institutions. Maïlys Ferrère is a member of the Boards of Directors or Supervisory boards of the following companies: DBV, Valneva SE, Pixium, Gensight and Euronext Paris. Professor Jean-Charles Soria is a medical oncologist and a Professor of Medicine and Medical Oncology at South-Paris University. He is a full-time cancer specialist at Institut Gustave Roussy. Professor Soria trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997. He gained a postgraduate degree and a PhD degree in molecular biology (fundamental basis of oncogenesis) in 2001, and completed his training with a two-year post-doctoral fellowship at MD Anderson Cancer Center, Houston, USA, where he has held an Adjunct Professorship since 2012. Professor Soria is also a member of the thoracic pathology committee at Gustave Roussy Cancer Center. He is a recognized expert on targeted therapies, immunotherapy and lung cancer. His main research interests are: early clinical development, pharmacodynamic biomarkers, lung cancer, immunotherapy and personalized medicine. He is also involved in translational research aspects related to precision medicine and tumor progression notably in lung cancer models (INSERM unit 981). Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight Paris time, will be able to attend. Shareholders holding "au porteur" (bearer) shares will need to obtain an "attestation de participation" (certificate of shareholding) from their brokers. This "attestation de participation" must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The "attestation de participation" may replace the admission card for shareholders wishing to attend the AGM in person. Written questions from shareholders must be received from the day of the publication of the official convocation to the AGM up until four business days prior to the AGM (by registered letter, addressed to the registered office, or by e-mail to investors@innate-pharma.com). Shareholders may obtain the legal documentation in preparation of the AGM (as described in article R. 225-83 of the French "Code de Commerce") by sending a request: Innate Pharma S.A. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The Company's aim is to become a fully-integrated biopharmaceutical company in the area of immunotherapy and focused on serious unmet medical needs in cancer. Innate Pharma has pioneered the discovery and development of checkpoint inhibitors to activate the innate immune system. Innate Pharma's innovative approach has resulted in three first-in-class, clinical-stage antibodies targeting natural killer cell receptors that may address a broad range of solid and hematological cancer indications as well as additional preclinical product candidates and technologies. Targeting receptors involved in innate immunity also creates opportunities for the Company to develop therapies for inflammatory diseases. The Company's expertise and understanding of natural killer cell biology have enabled it to enter into major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb and Sanofi. Based in Marseille, France, Innate Pharma has more than 170 employees and is listed on Euronext Paris. Learn more about Innate Pharma at www.innate-pharma.com. This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.


News Article | May 23, 2017
Site: globenewswire.com

INNATE PHARMA TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON JUNE 23, 2017 Innate Pharma (the "Company" - Euronext Paris: FR0010331421 - IPH) will hold its Annual General Meeting of Shareholders ("AGM") on June 23, 2017, at 10:00 am in its headquarters, 117 avenue de Luminy, F-13009 Marseille. The Notice of Meeting of this Shareholders' Meeting was published on May 19, 2017, in the French official legal bulletin ("BALO"). It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this Meeting. It is also available . All documentation regarding this AGM will be made available to shareholders in accordance with existing regulations and will be available on the Company's website as of today . Among the resolutions, the following will be proposed during the AGM: Professor Jean-Charles Soria will replace Professor Michael Caligiuri, who has been named American Association for Cancer Research (AACR) President and resigned from the Supervisory board. Hervé Brailly, Chairman of the Supervisory board, commented: "On behalf of all Supervisory board members, I would like to express our deepest gratitude to Professor Caligiuri, who has just been named President of AACR, one of the most prestigious worldwide cancer associations, for his commitment to the Board during the four years of his mandate. His medical expertise and experience have been valuable assets to the Board. We propose the appointment of Professor Jean-Charles Soria to succeed him. Professor Jean-Charles Soria is an oncologist, Head of Drug Development department at Gustave Roussy cancer center, and a renowned world leader in the field of immuno-oncology. We are also pleased to propose the appointment of Bpifrance Participations, represented by Maïlys Ferrère. Bpifrance Participations holds Innate Pharma's shares since 2009 and has supported the Company ever since. This appointment of Bpifrance Participations as member of the Supervisory board shows once again their commitment to Innate Pharma. These proposals guarantee the wealth, diversity and complementarity of profiles which composed the Board and we will pursue our work thanks to the expertise of each of its members." Maïlys Ferrère is Director of the Large Venture Investment Pole within the Innovation Division of Bpifrance. Large Venture's mission is to provide long term capital to innovative French companies in areas with very strong growth with the goal of creating world leaders. The portfolio currently includes thirty companies in life sciences, digital and environmental technologies. Prior to this position, Maïlys Ferrère was an Investment Director at the Strategic Investment Fund between 2009 and 2012. She previously had a career in banking, specialized in equity capital markets in various financial institutions. Maïlys Ferrère is a member of the Boards of Directors or Supervisory boards of the following companies: DBV, Valneva SE, Pixium, Gensight and Euronext Paris. Professor Jean-Charles Soria is a medical oncologist and a Professor of Medicine and Medical Oncology at South-Paris University. He is a full-time cancer specialist at Institut Gustave Roussy. Professor Soria trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997. He gained a postgraduate degree and a PhD degree in molecular biology (fundamental basis of oncogenesis) in 2001, and completed his training with a two-year post-doctoral fellowship at MD Anderson Cancer Center, Houston, USA, where he has held an Adjunct Professorship since 2012. Professor Soria is also a member of the thoracic pathology committee at Gustave Roussy Cancer Center. He is a recognized expert on targeted therapies, immunotherapy and lung cancer. His main research interests are: early clinical development, pharmacodynamic biomarkers, lung cancer, immunotherapy and personalized medicine. He is also involved in translational research aspects related to precision medicine and tumor progression notably in lung cancer models (INSERM unit 981). Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight Paris time, will be able to attend. Shareholders holding "au porteur" (bearer) shares will need to obtain an "attestation de participation" (certificate of shareholding) from their brokers. This "attestation de participation" must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The "attestation de participation" may replace the admission card for shareholders wishing to attend the AGM in person. Written questions from shareholders must be received from the day of the publication of the official convocation to the AGM up until four business days prior to the AGM (by registered letter, addressed to the registered office, or by e-mail to investors@innate-pharma.com). Shareholders may obtain the legal documentation in preparation of the AGM (as described in article R. 225-83 of the French "Code de Commerce") by sending a request: Innate Pharma S.A. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The Company's aim is to become a fully-integrated biopharmaceutical company in the area of immunotherapy and focused on serious unmet medical needs in cancer. Innate Pharma has pioneered the discovery and development of checkpoint inhibitors to activate the innate immune system. Innate Pharma's innovative approach has resulted in three first-in-class, clinical-stage antibodies targeting natural killer cell receptors that may address a broad range of solid and hematological cancer indications as well as additional preclinical product candidates and technologies. Targeting receptors involved in innate immunity also creates opportunities for the Company to develop therapies for inflammatory diseases. The Company's expertise and understanding of natural killer cell biology have enabled it to enter into major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb and Sanofi. Based in Marseille, France, Innate Pharma has more than 170 employees and is listed on Euronext Paris. Learn more about Innate Pharma at www.innate-pharma.com. This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.


News Article | May 18, 2017
Site: www.prnewswire.com

"Our recent financing enables us to remain on-track to initiate the pivotal Phase 3 clinical trial of VAL-083 in refractory GBM. This milestone, combined with VAL-083's recent scientific advancements form the foundation for this molecule to serve as a platform asset addressing unmet medical needs in a broad range of tumor types including GBM, non-small cell lung cancer, ovarian cancer and other solid tumors both as a single agent and as a key component of combination therapy regimens," stated Jeffrey Bacha DelMar's chairman & CEO. In April, the Company announced the closing of a $9 million offering of common stock and warrants which was led by leading healthcare dedicated institutional investors. During the quarter, the Company made key advancements for VAL-03 as a treatment for GBM patients whose tumors express features, such as high expression of the enzyme MGMT, that make their cancer resistant to, or unlikely to, respond to currently available therapy.  Accomplishments achieved included submitting a protocol to the FDA for a pivotal, controlled Phase 3 Study in Temozolomide-Avastin Recurrent GBM ("STAR-3") to evaluate overall survival versus salvage chemotherapy for GBM patients who have previously failed both temozolomide (Temodar™) and bevacizumab (Avastin™). The Company also announced a collaboration with PRA Health Sciences ("PRA") as the contract research organization to oversee and manage the Company's pivotal VAL-083 STAR-3 GBM clinical trial. PRA Health Sciences is one of the world's leading global contract research organizations, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA's global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 13,000 employees worldwide. During the period, the Company also continued enrolling its Phase 2 clinical study of VAL-083 in patients with MGMT-unmethylated GBM at first recurrence/progression prior to bevacizumab (Avastin®) exposure in collaboration with the University of Texas MD Anderson Cancer Center ("MD Anderson"). Additionally, DelMar received ethics committee approval, retained a contract research organization, and submitted an application to the China Office of Human Genetic Resources Authority ("OHGRA") to allow for initiation of the Company's planned Phase 2 clinical trial in newly diagnosed patients with MGMT-unmethylated GBM at Sun Yat Sen University in Guangzhou, China. DelMar also entered into a sponsored research agreement with Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar also continued to present promising research results supporting the potential of VAL-083 in the treatment of a range of cancers, including GBM, at leading scientific conferences. The Company presented data supporting the effectiveness of VAL-083 against chemotherapy-resistant ovarian cancers at the 11th Biennial Ovarian Cancer Research Symposium. Additionally, data was presented indicating that VAL-083 offers potential therapeutic alternatives in difficult-to-treat pediatric brain tumors – Advances in Pediatric Research: From Mechanisms and Models to Treatment and Survivorship. In April, new non-clinical data supporting the differentiation of VAL-083 in the treatment of lung cancer was presented at the American Association for Cancer Research's ("AACR") annual meeting. And in May, the Company presented new research at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies demonstrating that VAL-083 circumvents both of the primary mechanisms correlated to chemoresistance to temozolomide, the current standard of care in the treatment of GBM. "GBM represents one of the few cancers that has been largely left behind in the tremendous medical advancements of modern cancer care.  Success in our GBM clinical trials will provide VAL-083 as a new treatment for patients who currently have no viable therapeutic option," said Mr. Bacha.  "Our research with VAL-083 also seeks to expand this opportunity beyond GBM to a wide range of solid tumor patients whose cancer is resistant or unlikely to respond to currently available treatments.  Unlocking the value of VAL-083 for our patients and our shareholders is our primary goal." DelMar plans to host a conference call to discuss quarterly results and provide a corporate update on Wednesday, May 24th, 2017, at 4:30 p.m. Eastern Standard Time. For both "listen-only" participants and those who wish to take part in the question and answer portion of the call, the telephone Dial-in Number is 800‑894‑5910 (toll free) with Conference ID DELMAR. Listeners can also attend the call via webcast https://engage.vevent.com/rt/delmar_ao~051817.  A link to the webcast and slides will be archived on the IR Calendar of the Investors section of the Company's website at www.delmarpharma.com and will be available for 30 days following the webcast. SUMMARY OF FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2017; THIRD QUARTER OF FISCAL YEAR 2017 For the three months ended March 31, 2017 the Company reported a net loss of $1,868,460 or $0.18 per share, compared to a net loss of $1,140,401, or $0.10 per share for the three months ended March 31, 2016. For the nine months ended March 31, 2017 the Company reported a net loss of $5,480,772 or $0.54 per share, compared to a net loss of $5,408,479, or $0.50 per share for the nine months ended March 31, 2016. Our quarterly expenditures during the current fiscal year to date have been consistent and reflect increased activities being undertaken in preparation for initiation of our planned pivotal Phase 3 clinical trial. The following represents selected financial information as of March 31, 2017. The Company's financial information has been prepared in accordance with U.S. GAAP and this selected information should be read in conjunction with DelMar's consolidated financial statements and management's discussion and analysis ("MD&A"), as filed. DelMar's financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the company's website at: http://ir.delmarpharma.com/all-sec-filings. Excluding the impact of non-cash expense, research and development expenses increased to $968,332 during the three months ended March 31, 2017 from $660,857 for the three months ended March 31, 2016.  The difference was largely attributable to an increase in clinical research and intellectual property costs.  Clinical research costs have increased due to protocol development and manufacturing activities conducted in preparation for our pending pivotal Phase 3 clinical trial in refractory GBM, our two Phase 2 clinical trials in MGMT-unmethylated GBM as well as an expansion of our preclinical and other research activities compared to the prior period. Excluding the impact of non-cash expenses, general and administrative expenses increased in the three months ended March 31, 2017 to $635,769 from $517,030 for the three months ended March 31, 2016.  The increase was largely attributable to activities undertaken in preparation for our recent financing. We estimate that our current working capital, including proceeds from our recent financing is sufficient to support our planned operations for the next 18-24 months. VAL-083 is a "first-in-class," small-molecule chemotherapeutic. In more than 40 Phase I and II clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated clinical activity against a range of cancers including lung, brain, cervical, ovarian tumors and leukemia both as a single-agent and in combination with other treatments. VAL-083 has received an orphan drug designation in Europe for the treatment of malignant gliomas and the U.S. FDA Office of Orphan Products has granted an orphan designation to VAL-083 for the treatment of glioma, medulloblastoma and ovarian cancer. DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients. For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989. Connect with the Company on Twitter, LinkedIn, Facebook, and Google+. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-announces-third-quarter-fiscal-year-2017-financial-results-300460433.html


ARLINGTON, VA; May 17, 2017 - One hundred high school students from 29 states have been named winners in the second year of PBS LearningMedia's and Stand Up To Cancer's Emperor Science Award program. The Emperor Science Award program is an initiative designed to encourage high school students to explore careers in science, specifically cancer research and care, through a unique mentoring opportunity. PBS LearningMedia, a digital educational resource library for teachers and students, and Stand Up To Cancer, a program of the Entertainment Industry Foundation, received nearly 800 applications from eligible 10th and 11th grade students in 44 states throughout the U.S. who are interested in pursuing a career in science research. Prominent scientists served as judges and evaluated the students' applications: written essays submitted online January 10 through March 17, addressing why scientific research is so important in finding a cure for cancer, what scientific field they would study and why. Two of the Awardees are students receiving support for a second year of mentorship, as allowed by the program. "After an amazing inaugural year, we are proud to welcome a new class of students to the Emperor Science Award mentorship program," said Sara Schapiro, Vice President, PBS Education. "The students selected for this year's class are leaders in their schools and communities and it is our hope that through this unique opportunity they are able to tangibly explore careers in cancer research. I wish to personally congratulate them on all they have already accomplished and am looking forward to their future success." The 100 Emperor Science Award recipients will have an opportunity to conduct research in a lab, virtually, or a combination of both, working with an esteemed scientist on a rewarding multi-week cancer research project, will receive a Google Chrome computer to enhance their studies and to facilitate mentor access for those students who live at a distance from their mentor's research facility, and a $1,500 stipend for expenses. Those entering the program for the first year will also have the opportunity to apply for a second year. The Emperor Science Award Program extends the learning and outreach for the PBS documentary, Ken Burns Presents CANCER: THE EMPEROR OF ALL MALADIES A Film by Barak Goodman. "It is so exciting to see in these applications the passion, interest and commitment of these students to pursue cancer research," said Sherry Lansing, co-founder of Stand Up To Cancer, and chairperson of the committee of documentary production supporters which conceived of the Emperor Science Award Program. "We hope that giving these students this opportunity and support may strengthen their resolve and hone their interest so that they might possibly become the next generation of researchers who will help more cancer patients become long-term survivors. Cancer affects one in two men, one in three women in the United States, and too many of these students had already experienced cancer in their families and communities and a few are cancer survivors themselves." Students from rural, suburban and urban communities in 29 states comprise the second class of Emperor Science Awardees. These students demonstrated awareness of emerging developments in cancer treatment, including precision medicine, immunotherapy and epigenetics, and have an impressive range of research focuses and interests, including nanotechnology and engineering, basic cellular biology, gene mapping, bioinformatics, DNA splicing and computational sciences. The Emperor Science Award Program has been made possible by generous financial support from Founding Donors Genentech, a member of the Roche Group, Bristol-Myers Squibb Company and Novartis. Their support will fund a total of 300 awards through the first three years. "We are inspired by this year's scholarship winners and proud to support their interest in science," said Ann Lee-Karlon, senior vice president, Portfolio Management and Operations at Genentech. "We believe in the power of mentoring and the value of human connections. Mentoring relationships provide students with insight and encouragement, opening doors to a wide range of future careers." "Congratulations to the recipients of this year's Emperor Science Award," said Awny Farajallah, MD, vice president, head of U.S. Medical Oncology at Bristol-Myers Squibb. "This competitive program is unique in encouraging and enabling bright, young students to further cultivate their interests in science and cancer research. We're hopeful that many students will be inspired to explore careers to help improve care for people living with cancer." "It is an honor to continue our support of the Emperor Science Awards," said Bill Hinshaw, Executive Vice President and Head, US Novartis Oncology. "It is our hope that science-based mentorship programs like this will inspire our youth to become the scientists of our future." The full list of Emperor Science Award recipients is available at http://www. . For more information on PBS LearningMedia, visit http://www. . Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry's resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease. As SU2C's scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, PhD, conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress. Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, Ellen Ziffren, and Kathleen Lobb. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Sung Poblete, PhD, RN, has served as SU2C's president since 2011. As America's largest classroom, PBS offers digital content and services for teachers of children from pre-K through 12th grade that help bring classroom lessons to life. PBS LearningMedia, a partnership of PBS and WGBH Educational Foundation, is a free and paid media-on-demand service offering educators access to the best of public media and delivers research-based, classroom-ready digital learning experiences to engage students in exploring curriculum concepts that align with National and Common Core State Standards. Nationwide, more than 1.8 million teachers and users have registered access to more than 100,000 digital resources available through PBS LearningMedia. More information about PBS LearningMedia is available at http://www. or by following PBS LearningMedia on Twitter and Facebook. Founded 41 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www. . Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook. Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www. .

Loading American Association for Cancer Research collaborators
Loading American Association for Cancer Research collaborators